000			04205nam a22003735i 4500
001			289223
003			MX-SnUAN
005			20170705134219.0
007			cr nn 008mamaa
008			150903s2005 xxu| o |||| 0|eng d
020			_a9781592598717 _99781592598717
024	7		_a10.1385/1592598714 _2doi
035			_avtls000342827
039		9	_a201509031105 _bVLOAD _c201405070519 _dVLOAD _y201402061136 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC870-923.2
100	1		_aBroderick, Gregory A. _eeditor. _9319344
245	1	0	_aOral Pharmacotherapy for Male Sexual Dysfunction : _bA Guide to Clinical Management / _cedited by Gregory A. Broderick.
264		1	_aTotowa, NJ : _bHumana Press, _c2005.
300			_brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aCurrent Clinical Urology
500			_aSpringer eBooks
505	0		_aPhysiology and Pharmacology of Erectile Dysfunction -- Epidemiology of Erectile Dysfunction -- Pharmacology of Phosphodiesterase Inhibitors -- Sildenafil Citrate, the Classic PDE5 Inhibitor -- Tadalafil -- Vardenafil Clinical Trials Experience -- Erectile Dysfunction Assessment and Management in Primary Care Practice -- When to Refer the Patient With Erectile Dysfunction to a Specialist -- Erectile Dysfunction -- Is Diabetic Erectile Dysfunction More Difficult to Treat? -- Depression and Antidepressant-Associated Erectile Dysfunction -- Intracavernous, Transurethral, and Topical Therapies for Erectile Dysfunction in the Era of Oral Pharmacotherapy -- Androgen Deficiency in the Aging Male -- Central Activation of Erection and Clinical Experience -- Sustaining the Cure -- Prevention and Treatment of Erectile Dysfunction Utilizing Lifestyle Changes and Dietary Supplements -- Pharmacological Strategies in the Management of Rapid Ejaculation -- Sexual Dysfunction After Radical Prostatectomy and the Use of PDE-5 Inhibitors -- Female Sexual Dysfunction.
520			_aWith the advent of such oral drugs as Viagra®, Cialis®, and Levitra® for the treatment of erectile dysfunction (ED), the burden of first patient evaluation has fallen on the primary care provider. In Oral Pharmacotherapy for Male Sexual Dysfunction: A Guide to Clinical Management, highly experienced urologists and physician researchers review each aspect of male sexual dysfunction (interest, performance, and orgasm) and their implications for treatment. The authors address a wide variety of clinical issues, ranging from common medical risk factors for ED to the evaluation and management of men who have atypical presentations that require focused testing; from diabetic ED to the safety assessment of PDE inhibitors for cardiac patients; and from combination drug therapy for refractory patients to neuropharmacological therapies. Guidance is also provided for vacuum erection devices and surgical implants, the role of self-medication with dietary supplements, the management of post-prostatectomy ED, and the emerging pharmaceutical therapies for rapid ejaculation. On the pharmaceutical side, the authors summarize the pharmacology and development of PDE-type 5 inhibitors, review the preclinical data and 5 years of postmarketing data on Viagra®, examine the preclinical data on Levitra®, and discuss the design and conduct of US clinical trials of Cialis®. Authoritative and informative, Oral Pharmacotherapy for Male Sexual Dysfunction: A Guide to Clinical Management clarifies for urologists, family physicians, and internists each of the diagnostic approaches to male sexual dysfunction, as well as the pharmacological strategies available for its safe and effective management.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781588294517
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1385/1592598714 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c289223 _d289223